What are the insider’s Celldex (CLDX) share holdings after the reported transactions?

Following the reported transactions, the insider directly owned 20,833 shares of Celldex common stock and 7,875 derivative securities (options) directly.

Celldex Therapeutics Form 4 shows major insider option exercises

Q: What insider transaction did Celldex Therapeutics (CLDX) report on this Form 4?

The Form 4 reports that an insider of Celldex Therapeutics (CLDX) exercised incentive stock options and sold common shares on 11/13/2025 , changing their direct holdings.

Q: How many Celldex (CLDX) shares did the insider sell and at what price?

The insider sold 49,298 shares of Celldex common stock at a weighted average price of $24.0005 per share, with individual trades executed between $24.00 and $24.05 .

Q: How many Celldex (CLDX) options did the insider exercise in this filing?

The insider exercised incentive stock options covering 6,876 shares at $9.0165 , 26,672 shares at $10.38 , and 15,750 shares at $22.48 on 11/13/2025 .

Q: What vesting information is disclosed for the Celldex (CLDX) stock options?

The filing notes that one option was fully vested as of June 13, 2022 , another as of June 18, 2024 , and a third vested 25% on June 16, 2023 with the remainder vesting quarterly in equal amounts over the following 12 quarters.

Q: Is the Celldex (CLDX) Form 4 transaction linked to a Rule 10b5-1 trading plan?

The form includes a checkbox for trades made under a Rule 10b5-1(c) trading plan, but the excerpt does not show whether it was checked.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Celldex Therapeutics (CLDX) filed a Form 4 reporting option exercises and a share sale by an insider. On 11/13/2025, the reporting person exercised three incentive stock options for 6,876 shares at $9.0165, 26,672 shares at $10.38, and 15,750 shares at $22.48, receiving common stock in each case. On the same date, they sold 49,298 common shares at a weighted average price of $24.0005 per share, with trades executed between $24.00 and $24.05. After these transactions, the insider directly owned 20,833 common shares and held 7,875 derivative securities (options) directly.

Insider Trade Summary

Net Seller: 49,298 shares ($1,183,177)

Net Sell 7 txns

Insider Wright Richard M.

Role Insider

Sold 49,298 shs ($1.18M)

Type	Security	Shares	Price	Value
Exercise	Incentive Stock Option	6,876	$0.00	--
Exercise	Incentive Stock Option	26,672	$0.00	--
Exercise	Incentive Stock Option	15,750	$0.00	--
Exercise	Common Stock	6,876	$9.0165	$62K
Exercise	Common Stock	26,672	$10.38	$277K
Exercise	Common Stock	15,750	$22.48	$354K
Sale	Common Stock	49,298	$24.0005	$1.18M

Holdings After Transaction: Incentive Stock Option — 0 shares (Direct); Common Stock — 27,709 shares (Direct)

Footnotes (1)

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. As of June 13, 2022, the option is fully vested. As of June 18, 2024, the option is fully vested. 25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Form 4 Insider Transactions: What Each Field Means →

11/17/2025 - 04:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wright Richard M.

(Last)

(First)

(Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON

08827

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		Former Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/13/2025		M		6,876	A	$9.0165	27,709	D
Common Stock	11/13/2025		M		26,672	A	$10.38	54,381	D
Common Stock	11/13/2025		M		15,750	A	$22.48	70,131	D
Common Stock	11/13/2025		S		49,298	D	$24.0005⁽¹⁾	20,833	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Incentive Stock Option	$9.0165	11/13/2025		M			6,876	⁽²⁾	06/13/2028	Common Stock	6,876	$0	0	D
Incentive Stock Option	$10.38	11/13/2025		M			26,672	⁽³⁾	06/18/2030	Common Stock	26,672	$0	0	D
Incentive Stock Option	$22.48	11/13/2025		M			15,750	⁽⁴⁾	06/16/2032	Common Stock	15,750	$0	7,875	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

2. As of June 13, 2022, the option is fully vested.

3. As of June 18, 2024, the option is fully vested.

4. 25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

	/s/ Sam Martin, attorney-in-fact for Richard M. Wright	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Celldex Therapeutics (CLDX) report on this Form 4?

The Form 4 reports that an insider of Celldex Therapeutics (CLDX) exercised incentive stock options and sold common shares on 11/13/2025, changing their direct holdings.

How many Celldex (CLDX) shares did the insider sell and at what price?

The insider sold 49,298 shares of Celldex common stock at a weighted average price of $24.0005 per share, with individual trades executed between $24.00 and $24.05.

How many Celldex (CLDX) options did the insider exercise in this filing?

The insider exercised incentive stock options covering 6,876 shares at $9.0165, 26,672 shares at $10.38, and 15,750 shares at $22.48 on 11/13/2025.

What vesting information is disclosed for the Celldex (CLDX) stock options?

The filing notes that one option was fully vested as of June 13, 2022, another as of June 18, 2024, and a third vested 25% on June 16, 2023 with the remainder vesting quarterly in equal amounts over the following 12 quarters.

Is the Celldex (CLDX) Form 4 transaction linked to a Rule 10b5-1 trading plan?

The form includes a checkbox for trades made under a Rule 10b5-1(c) trading plan, but the excerpt does not show whether it was checked.